This trial tests the accuracy of PET imaging to detect Alzheimer's disease in living patients, compared to post-mortem brain autopsies.
1 Primary · 4 Secondary · Reporting Duration: At autopsy, until study completion with an average of 1 year
1 Treatment Group
PI-2620 PET Scan
1 of 1
200 Total Participants · 1 Treatment Group
Primary Treatment: PI-2620 PET Scan · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is enrollment for this investigation ongoing?
"Based on the information found at clinicaltrials.gov, this specific trial is no longer recruiting participants. After first being posted in December of 2022 it was last updated five days later with 555 other trials actively looking for candidates presently." - Anonymous Online Contributor
What potential hazards are associated with PI-2620 PET Scans?
"Through rigorous testing, PI-2620 PET Scan has been evaluated to be of a high level of safety as indicated by its score of 3 on Power's scale. This is due to existing evidence that suggests efficacy and multiple tests confirming safety." - Anonymous Online Contributor